Spots Global Cancer Trial Database for stage iii urethral cancer ajcc v8

Every month we try and update this database with for stage iii urethral cancer ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	NCT02496208	Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study	NCT05092958	Advanced Bladde... Advanced Renal ... Advanced Ureter... Advanced Urethr... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Stage III Bladd... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr...	Avelumab Biospecimen Col... Bone Scan Cabozantinib S-... Computed Tomogr... Magnetic Resona... Quality-of-Life... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	NCT02496208	Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma	NCT03513952	Advanced Bladde... Advanced Ureter... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Glycosylated Re... Laboratory Biom... Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer	NCT03617913	Bladder Carcino... Stage II Bladde... Stage II Renal ... Stage II Ureter... Stage II Urethr... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Urethral Urothe...	Avelumab Cisplatin Fluorouracil Mitomycin Quality-of-Life... Radiation Thera...	18 Years -	Mayo Clinic
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer	NCT00749892	Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage 0a Bladde... Stage 0a Renal ... Stage 0a Ureter... Stage 0a Urethr... Stage 0is Bladd... Stage 0is Renal... Stage 0is Urete... Stage 0is Ureth... Stage II Bladde... Stage II Renal ... Stage II Ureter... Stage II Urethr... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad...	Erlotinib Hydro...	19 Years -	M.D. Anderson Cancer Center
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer	NCT00749892	Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage 0a Bladde... Stage 0a Renal ... Stage 0a Ureter... Stage 0a Urethr... Stage 0is Bladd... Stage 0is Renal... Stage 0is Urete... Stage 0is Ureth... Stage II Bladde... Stage II Renal ... Stage II Ureter... Stage II Urethr... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad...	Erlotinib Hydro...	19 Years -	M.D. Anderson Cancer Center
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	NCT04940299	Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Malignant Solid... Metastatic Blad... Metastatic Blad... Metastatic Lung... Metastatic Mela... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Uret... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Lung ... Stage IVB Lung ... Unresectable Me...	Ipilimumab Nivolumab Tocilizumab	18 Years -	M.D. Anderson Cancer Center
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer	NCT03617913	Bladder Carcino... Stage II Bladde... Stage II Renal ... Stage II Ureter... Stage II Urethr... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Urethral Urothe...	Avelumab Cisplatin Fluorouracil Mitomycin Quality-of-Life... Radiation Thera...	18 Years -	Mayo Clinic
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate	NCT03582475	Bladder Small C... Castration-Resi... Metastatic Blad... Metastatic Uret... Prostate Carcin... Prostate Neuroe... Prostate Small ... Stage III Bladd... Stage III Prost... Stage III Ureth... Stage IV Bladde... Stage IV Prosta... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Ureter Small Ce... Urothelial Carc...	Carboplatin Cisplatin Docetaxel Etoposide Pembrolizumab	18 Years -	Jonsson Comprehensive Cancer Center
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer	NCT03237780	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Eribulin Mesyla...	18 Years -	National Cancer Institute (NCI)
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer	NCT03237780	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Eribulin Mesyla...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: